# Prolaris

Source: https://onco.cc/drugs/prolaris/  
OnCo record `prolaris` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A gene test on a prostate biopsy that estimates how aggressive the cancer is, to help decide between active surveillance and treatment.

## Summary

Prolaris (Myriad Genetics) measures how fast tumour cells are dividing and reports a 10-year risk of dying from prostate cancer under conservative management and of metastasis after treatment. It is listed in NCCN guidelines as an option for men with low or favourable-intermediate risk disease considering active surveillance, is covered by Medicare, and validated in conservatively managed UK cohorts and US surgical series. Like Decipher and Oncotype DX GPS it refines, rather than replaces, PSA, Gleason grade and MRI; head-to-head comparisons are few and none of the three has randomised evidence that its use improves outcomes.

## Fields

- Kind: Treatment
- Status: established
- Last checked: 2026-09-10
- Tags: test
- Brand: Prolaris
- Modality: Gene-expression prognostic assay (cell-cycle progression score, prostate)
- Mechanism: RT-PCR of 31 cell-cycle progression genes and 15 housekeeping genes on biopsy tissue, combined with clinical risk (CAPRA) to estimate 10-year prostate cancer mortality and metastasis risk.

## Notes

- What a result means: a low score supports active surveillance; a high score in an otherwise low-risk cancer argues for treatment.

## Sources

- Myriad: Prolaris (page moved; nearest live section): https://myriad.com/oncology/

## Connected records

- drugs: [Decipher Prostate](https://onco.cc/drugs/decipher-prostate/), [Oncotype DX Genomic Prostate Score](https://onco.cc/drugs/oncotype-dx-gps/)
- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [Active surveillance](https://onco.cc/technologies/active-surveillance/), [Gene-expression prognostic assays](https://onco.cc/technologies/gene-expression-prognostic-assays/), [RNA sequencing & expression profiling](https://onco.cc/technologies/rna-seq/)
- companies: [Myriad Genetics](https://onco.cc/companies/myriad-genetics/)
- terms: [Active surveillance and observation](https://onco.cc/terms/active-surveillance-term/), [Gleason score / Grade Group](https://onco.cc/terms/gleason-grade-group/), [PSA (prostate-specific antigen)](https://onco.cc/terms/psa/)

---
JSON: https://onco.cc/api/v1/entities/prolaris.json